Marie Bradley, Ph.D., M.P.H., M.Pharm.
Cancer Prevention Fellow, Clinical and Translational Epidemiology Branch
- Telephone: (240) 276-6883
- Fax: (240) 276-7921
- E-mail: email@example.com
Epidemiology and Genomics Research Program
Division of Cancer Control and Population Sciences
National Cancer Institute
National Institutes of Health
9609 Medical Center Drive, Rm. 4E320, MSC 9763
Bethesda, MD 20892
(For express delivery, use Rockville, MD 20850)
- Effects of routinely used medications on cancer risk and disease prevention.
- Adverse and/or long-term effects of chemotherapeutic and other pharmacologic agents used in the treatment of cancer.
- Ph.D. – Pharmacoepidemiology
Queens University Belfast
- M.P.H. – Public Health (General stream)
London School of Hygiene and Tropical Medicine
- M.Pharm. – Masters in Pharmacy
Queens University of Belfast
Dr. Marie Bradley is a Cancer Prevention Fellow with the Clinical and Translational Epidemiology Branch (CTEB) of the Epidemiology and Genomics Research Program (EGRP). In this role, she will undertake pharmacoepidemiological research in relation to the risk and progression of cancer associated with the use of routinely used drugs and the long term adverse effects of cancer treatments, such as the development of cardiotoxicities and second cancers.
Dr. Bradley is a pharmacist and, during her Ph.D. in Pharmacoepidemiology, she investigated the association between exposure to routinely used drugs, such as statins, proton pump inhibitors (PPIs), aspirin and non-steroidal anti-inflammatory drugs (NSAIDs), and pancreatic cancer risk and survival using the United Kingdom (UK) Clinical Practice Research Datalink (CPRD). Upon completion of her Ph.D., Dr. Bradley was awarded a 5-year post-doctoral fellowship in the Health Research Board Centre for Primary Care Research, a joint collaboration between Queen’s University Belfast, Royal College of Surgeons in Ireland, and Trinity College Dublin. Her post-doctoral research focused on investigating the prevalence and predictors of potentially inappropriate prescribing (PIP), among older adults, in the UK and Northern Ireland (NI) using CPRD and other smaller prescribing databases in NI. She was involved in designing and developing interventions to reduce PIP which were aimed at primary care physicians in Ireland.
Patterson SM, Hughes C, Kerse N, Cardwell CR, Bradley MC. Interventions to improve the appropriate use of polypharmacy for older people. Cochrane Database Systematic Reviews. 2012 May 16; 5: CD008165.
Bradley MC, Fahey T, Cahir C, Bennett K, O'Reilly D, Parsons C, Hughes CM. Potentially inappropriate prescribing and cost outcomes for older people: a cross-sectional study using the Northern Ireland Enhanced Prescribing Database. Eur J Clin Pharmacol. 2012 Oct; 68(10):1425-33.
Bradley MC, Hughes CM, Cantwell MM, Napolitano G, Murray LJ. Non-steroidal anti-inflammatory drugs and pancreatic cancer risk: a nested case-control study. Br J Cancer. 2010 Apr 27; 102(9):1415-21.